Multiple Myeloma (MM) ECHO®: Advancing RRMM Care Through Communities of Practice: Educating Community-Based Hematologic/Oncologic Teams on the Use of BCMA-Directed BsAbs
Multiple myeloma remains an incurable disease, characterized by high relapse rates and a disproportionate impact on patients of African ancestry. Emerging B-cell maturation antigen (BCMA) bispecific antibodies (bsAbs) offer promising therapeutic potential in addressing this challenging landscape.
This series features interactive cases led by expert faculty. Developed by Boston University Chobanian and Avedisian School of Medicine in collaboration with the American Academy of Physician Associates, the Association of PAs in Oncology, HealthTree Foundation, and Med-IQ.
BCMA-Directed Bispecific Antibodies in Multiple Myeloma: Mechanisms of Action, Clinical Efficacy, and Emerging Therapeutics | 0.25
Learning Objectives
Learning Objectives
BCMA-Directed Bispecific Antibodies in Multiple Myeloma: Bridging Academic and Community Practice
Learning Objectives
Learning Objectives
Learning Objectives
Learning Objective
This activity is supported by educational grants from Pfizer Inc. and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
This series features interactive cases led by expert faculty. Developed by Boston University Chobanian and Avedisian School of Medicine in collaboration with the American Academy of Physician Associates, the Association of PAs in Oncology, HealthTree Foundation, and Med-IQ.
Sessions in the Series
BCMA-Directed Bispecific Antibodies in Multiple Myeloma: Mechanisms of Action, Clinical Efficacy, and Emerging Therapeutics | 0.25
Learning Objectives
- Explain the mechanism of action of BCMA-directed BsAbs
- Characterize the safety and efficacy of BCMA-directed BsAbs for the treatment of MM
- Appropriately incorporate BCMA-directed BsAbs into cases of patients with MM that are representative of clinical practice
Learning Objectives
- Describe the diagnosis, risk factors, prevention and management of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS)
- Recognize infectious complications associated with BCMA-directed bispecific antibodies and implement strategies for their prevention
- Establish and follow workflows and lines of communication for monitoring and managing BCMA bsAb treatment-related adverse events (TRAEs)
🔜New Sessions Coming
BCMA-Directed Bispecific Antibodies in Multiple Myeloma: Bridging Academic and Community Practice
Learning Objectives
- Define the role of academic centers and community practices in providing BCMA targeting BsABs
- Summarize the importance and benefits of CoPs to providing coordinated, multidisciplinary, and interprofessional care for patients with MM receiving BCMA-directed bsAbs
- Appropriately incorporate BCMA-directed bsAbs into cases of patients with MM that are representative of clinical practice
Learning Objectives
- Recognize the physical, emotional, and social quality of life (QoL) of patients treated with BCMA targeting BsABs
- Evaluate tools and strategies for assessing patient-reported outcomes and quality of life
- Develop personalized support plans that integrate multidisciplinary resources
Learning Objectives
- Identify and categorize barriers to accessing BCMA-directed therapies for patients with multiple myeloma
- Discuss the impact of these barriers on health outcomes in various contexts
- Propose evidence-informed strategies and policy solutions to mitigate these barriers
Learning Objective
- Appropriately incorporate BCMA-directed bsAbs into cases of patients with MM that are representative of clinical practice
Acknowledgement of Commercial Support
This activity is supported by educational grants from Pfizer Inc. and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.